Core Viewpoint - Pfizer's dividend is considered relatively safe as 2026 begins, despite concerns regarding its high payout ratios and upcoming patent expirations [1][12][14] Financial Performance - Pfizer reported earnings of over $9.4 billion in the first nine months of 2025, with a market capitalization exceeding $140 billion [1] - The company has a forward dividend yield of 6.9% and a high dividend payout ratio of 99.4%, indicating it is barely covering its dividend with earnings [3][1] Cash Flow Analysis - Pfizer generated free cash flow of $10.4 billion in the 12 months ending September 30, 2025, while paying out $9.7 billion in dividends, resulting in a free cash flow payout ratio of 93.3% [6][12] - The free cash flow payout ratio is viewed as less concerning compared to the earnings-based payout ratio [12] Dividend History - Pfizer has increased its dividend for 16 consecutive years and has declared dividends for 349 consecutive quarters since 1937, showcasing a strong track record [7][10] Management Commitment - Pfizer's management, including CEO Albert Bourla and CFO David Denton, has reaffirmed a strong commitment to maintaining and growing the dividend over time [10][9] Patent Expiration Concerns - The company faces a significant patent cliff with key drugs like Eliquis and Xeljanz losing U.S. patent exclusivity, which could impact earnings and cash flow [10][11] - Management believes that investments in newly acquired and launched products will help offset the losses from patent expirations [11]

Michael M. Santiago / Getty Images Quick Read BKLN holds X Corp senior secured loans with a 10.96% coupon representing 1.89% of the portfolio. The fund’s distributions dropped from $1.82 per share in 2024 to approximately $1.41 in 2025 as the Fed shifted toward rate cuts. BKLN returned 6.7% year-to-date through December 29 combining its 6.4% yield with modest price appreciation. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, t ...

Core Viewpoint - Verizon Communications is facing challenges despite its 6.6% dividend yield, which has been described as "sacrosanct" by the CEO, Daniel Schulman. The company has a history of increasing dividends for 19 consecutive years, but the growth has been modest compared to inflation [1][2][10]. Financial Performance - Verizon reported $134.8 billion in revenue for 2024 and serves 146.1 million wireless retail connections, covering 99% of Fortune 500 companies and 99% of the U.S. population with its 4G LTE service [5]. - The company has lost 30% of its market share since 2017 and is now ranked No. 3 in the telecom industry, indicating heightened competition [6]. - In the last quarter, Verizon lost 7,000 postpaid phone customers and laid off 13,000 employees, reflecting dissatisfaction with its performance [7]. Dividend Analysis - Verizon's dividend has increased by only 1.8% this year, which is below the annual inflation rate of 3%. Since 2020, the dividend has grown by 12%, also lagging behind inflation [2][12]. - The company declared a quarterly dividend of $0.69 per share, amounting to $2.92 billion in dividends next quarter, which is less than half of the $7 billion in cash flow from operating activities [10]. - Verizon has paid off $9.4 billion in debt over the last year, which is nearly equivalent to the $11.2 billion paid in dividends for 2024, allowing for potential flexibility in maintaining dividends [11]. Strategic Outlook - The new CEO aims to reclaim network leadership, with some positive indicators such as 306,000 net adds in the broadband segment, totaling 13.2 million subscribers [8]. - Efficiency gains have led to a record $7 billion in free cash flow for the company, marking a 17% year-over-year increase [9]. - While the dividend is expected to remain stable, future hikes may be minimal, making it less appealing for long-term investors due to inflation concerns [12].

Core Viewpoint - Bristol Myers Squibb (BMY) offers a high dividend yield of 5.4%, significantly above the S&P 500 average of 1.2%, but concerns about the sustainability of this dividend arise due to the company's declining stock performance and future growth challenges [2][3]. Financial Performance - Over the past five years, Bristol Myers has experienced a total return of negative 9%, contrasting sharply with the S&P 500, which has roughly doubled in value during the same period [3]. - The company anticipates revenue between $47.5 billion and $48 billion for the current year, indicating a slight decline from the previous year's $48.3 billion [4]. - Bristol Myers has generated $15.3 billion in free cash flow over the last 12 months, exceeding the $5 billion paid in dividends during that timeframe, suggesting current dividend sustainability [5]. Dividend Safety - The payout ratio for Bristol Myers is around 84%, which is considered high but still sustainable given the company's profitability [5]. - Despite the current safety of the dividend, concerns exist regarding its long-term viability due to the company's substantial net debt of $32 billion, which raises questions about future dividend cuts if financial conditions worsen [6][9]. Market Position and Valuation - Bristol Myers has a market capitalization of $100 billion and is currently trading at a forward price-to-earnings (P/E) multiple of less than 8, indicating it may appear undervalued [7][8]. - The company is investing in growth with around 50 compounds in development, but faces significant risks from upcoming patent expirations for key drugs like Opdivo and Eliquis, which could adversely affect revenue [7][8]. Investment Outlook - While the stock may seem cheap, it is viewed as a potential value trap rather than a solid investment opportunity at this time, especially given the high debt load and growth challenges [8][9]. - A cautious approach is recommended, as there are safer dividend-generating stocks available in the market [9].

Core Viewpoint - Pfizer is offering a high dividend yield of 6.9%, significantly above the S&P 500 average of 1.2%, yet this has not attracted investors, leading to a sluggish share price [1][2]. Financial Performance - Pfizer reported earnings per share of $0.62 in the third quarter, a decline of 20% from $0.78 in the same period last year [4]. - The company maintains a quarterly dividend of $0.43 per share, resulting in a payout ratio of just under 70%, which is considered healthy [4]. - Over the past 12 months, Pfizer generated $10.4 billion in free cash flow, exceeding the $9.7 billion paid out in dividends during the same period [6][7]. Investor Sentiment - Investors appear to have doubts about the sustainability of Pfizer's dividend and the company's future prospects, as indicated by the stock's performance [2][8]. - Despite strong financials supporting the current dividend payout, Pfizer's stock has declined nearly 6% this year and has lost close to half its value over the past three years [10].

Group 1: Smith & Wesson Brands - Smith & Wesson Brands is currently trading at $8.66, with a 52-week range of $8.38 to $16.85 and a dividend yield of 6.00% [2] - The company faces significant headwinds, including tariffs and revenue deleveraging, which have negatively impacted margins and led to insufficient income to cover the dividend [2][3] - The payout ratio is projected to exceed 150% by the end of fiscal 2025, raising concerns about the sustainability of the dividend [2][3] - Analysts have a consensus rating of Moderate Buy, but sentiment is declining, and the price target is falling, indicating potential further downside risk [4] Group 2: SunCoke Energy - SunCoke Energy is trading at $8.18, with a 52-week range of $7.47 to $12.82 and a dividend yield of 5.86% [6] - The company has headwinds from weaker coal prices; however, its dividend payment is considered safe due to long-term contracts that guarantee cash flow [6][7] - The payout ratio is expected to be around 70% in 2025, which is sustainable for the business [6] - A recent acquisition of Phoenix Global is anticipated to positively impact revenue and profitability, diversifying SunCoke's business [7] - MarketBeat tracks one analyst rating this stock as a Buy, with a price target over 65% above current trading levels, supported by strong institutional ownership [8] Group 3: Tronox Holdings - Tronox Holdings is trading at $5.67, with a 52-week range of $4.35 to $17.45 and a dividend yield of 8.82% [10] - The company reported a net loss for the previous fiscal year, but analysts believe it is at a turning point due to shifts in demand for TiO2 pigments [10][12] - The consensus rating among eight analysts is Moderate Buy, indicating potential for a 50% upside, with recent upgrades from JPMorgan raising the price target to $7 [11] - Tronox's balance sheet is strong enough to sustain the dividend until business conditions improve, with expectations of positive earnings by the end of the fiscal year [12]

Core Viewpoint - UnitedHealth Group's stock has experienced a significant decline of over 40% in 2025, yet it remains one of the largest healthcare companies with a market cap exceeding $270 billion [1] Financial Performance - The stock's dividend yield has risen to 2.8%, surpassing the S&P 500 average of 1.3%, which raises concerns about the potential risk to the dividend [2] - UnitedHealth's current payout ratio is approximately 35%, indicating a healthy buffer for dividend payments [5] - Over the last 12 months, UnitedHealth generated a free cash flow of $24.9 billion while paying out $7.7 billion in dividends, suggesting the dividend is secure as long as cash flow remains strong [6] Future Concerns - There are significant risks related to a criminal investigation into the company's billing practices and potential Medicare fraud, which could impact future financial stability [9] - The U.S. government's potential cuts to healthcare spending may pose additional challenges to the company's growth prospects [9] - Recent news of CEO Andrew Witty's resignation has further contributed to investor uncertainty [10] Investment Outlook - Despite current risks, the dividend appears safe, and the company plays a crucial role in providing healthcare coverage to millions [11] - The stock is trading at less than 13 times its trailing earnings, which is significantly lower than the S&P 500 average of just under 24, indicating potential long-term value for investors willing to endure short-term volatility [12][13]